Drug Discovery

Has China Now Overtaken the US at the Heart of Biotech Innovation?

Recent data from JPM2026 shows that China has surpassed the United States in key biotech activity measures—topping the…

ByByAnuja Singh Mar 4, 2026

Is Hong Kong Becoming Asia’s AI–Biopharma Hub?

Hong Kong is emerging as a key AI‑biopharma hub, with recent deals like Earendil Labs’ partnership with Sanofi…

ByByAnuja Singh Mar 4, 2026

Is Insilico’s AI Drug Engine “Einstein” Turning China into the Global AI–Pharma Hub?

Insilico Medicine’s AI‑driven drug discovery platform, Pharma.AI “Einstein,” is scaling fast in China, with a major expansion of…

ByByAnuja Singh Mar 4, 2026

Biotech Licensing Soars to $137B in 2025 – China Now Leads the Licensing Race

The global biotech licensing market hit a record $137 billion in 2025, and 2026 is on track to…

ByByAnuja Singh Mar 4, 2026
Image Not Found

Can Novartis AG’s $3 Billion AI-Driven Oncology Bet Redefine Precision Breast Cancer Treatment and Accelerate Next-Gen Drug Discovery?

Key Highlights: AI-Led Drug Discovery Accelerates Target Identification and ValidationNovartis AG’s acquisition of SNV4818 from Synnovation Therapeutics, Inc.…

ByByAnuja Singh Mar 24, 2026

How Will Emerging Drug Pricing Policies Reshape the Global Biopharma Industry in the Near and Long Term?

The global biopharmaceutical industry is entering a new policy-driven era as governments intensify efforts to control drug costs,…

ByByAnuja Singh Mar 6, 2026
Scroll to Top